迈得医疗：预计2025年全年归属净利润盈利约6652.13万元

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, projecting approximately 66.52 million yuan, driven by substantial growth in overall operating revenue and successful product delivery [1] Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of approximately 66.52 million yuan for the year 2025 [1] - The increase in revenue is attributed to the orderly implementation of production plans and a focus on technological innovation and process iteration [1] - The blood purification and drug-device combination intelligent equipment business is performing well, particularly due to strong demand growth in the terminal market for medical consumables [1] Group 2: Q3 Financial Results - For the first three quarters of 2025, the company's main revenue reached 225 million yuan, a year-on-year increase of 2.31% [2] - The net profit attributable to shareholders for the same period was 8.84 million yuan, reflecting a year-on-year increase of 15.82% [2] - In Q3 2025 alone, the company reported a main revenue of 83.64 million yuan, a significant year-on-year increase of 54.38% [2] - The net profit for Q3 2025 was 2.79 million yuan, showing a remarkable year-on-year increase of 224.07% [2] - The company reported a debt ratio of 29.86% and a gross profit margin of 40.19% [2]